• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by INNOVATE Corp.

    11/13/24 9:30:32 PM ET
    $VATE
    Metal Fabrications
    Industrials
    Get the next $VATE alert in real time by email
    SC 13G/A 1 ef20038553_sc13ga.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

    INNOVATE Corp.
     
    (Name of Issuer)

    Common Stock, par value $0.001 per share
     
    (Title of Class of Securities)
     

    45784J303
     

       

    (CUSIP Number)
     

    September 30, 2024
     
    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒
    Rule 13d-1(b)

    ☐
    Rule 13d-1(c)

    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section of the Exchange Act but shall be subject to all other provisions of the Exchange Act (however, see the Notes).



    CUSIP No. 45784J303
    13G

    1
    NAMES OF REPORTING PERSONS
     
     
    Jefferies LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    700,802 (see Item 4)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    700,802 (see Item 4)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    700,802 (see Item 4)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.3% (1) (see Item 4)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    BD
     
     
     
     

    (1) Based on 13,261,379 shares of Common Stock of the Issuer outstanding as of November 1, 2024 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024.


    CUSIP No. 45784J303
    13G

    1
    NAMES OF REPORTING PERSONS
     
     
    Jefferies Financial Group Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    New York
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    700,802 (1) (see Item 4)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    700,802 (1) (see Item 4)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    700,802 (1) (see Item 4)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.3% (1)(2) (see Item 4)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     

    (1) Includes all shares of Common Stock beneficially owned by Jefferies LLC.
    (2) Based on 13,261,379 shares of Common Stock of the Issuer outstanding as of November 1, 2024 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024.


    Item 1(a).
    Name of Issuer:

    INNOVATE Corp. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    295 Madison Avenue, 12th Floor, New York, NY 10017

    Item 2(a).
    Name of Person Filing:

    Jefferies LLC
    Jefferies Financial Group Inc.
    (each a “Reporting Person” and collectively, the “Reporting Persons”)

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:

    520 Madison Ave., New York, NY 10022

    Item 2(c).
    Citizenship:

    The responses of the Reporting Persons to Row 4 in each of their respective cover pages are incorporated herein by reference.

    Item 2(d).
    Title and Class of Securities:

    Common Stock, par value $0.001 per share, of the Issuer (the “Common Stock”)

    Item 2(e).
    CUSIP Number:

    45784J303

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c), Check Whether the Person Filing is a:

    (a)
    ☒
    Broker or dealer registered under Section 15 of the Exchange Act
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Exchange Act
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Exchange Act
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act
    (e)
    ☐
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E)
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F)
    (g)
    ☒
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)
    (h)
    ☐
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act
    (j)
    ☐
    A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J)
    (k)
    ☐
    Group, in accordance with Rule 13d-1(b)(1)(ii)(K)

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.
    Ownership.

    (a)-(c) The responses of the Reporting Persons to Rows 5, 6, 7, 8, 9 and 11 in each of their respective cover pages which relate to the beneficial ownership of Common Stock, as of September 30, 2024, are incorporated herein by reference.

    As of September 30, 2024, the Reporting Persons beneficially owned in the aggregate 700,802 shares of Common Stock, representing approximately 5.3% of the shares of Common Stock outstanding (based on 13,261,379 shares of Common Stock outstanding as of November 1, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2024).

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the Common Stock, check the following ☐.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Jefferies LLC is a broker or dealer registered under Section 15 of the Exchange Act and is a subsidiary of Jefferies Financial Group Inc., which have filed this Schedule 13G pursuant to Rule 13d‑1(b)(1)(ii)(G).

    Item 8.
    Identification and Classification of Members of the Group.

    Not applicable.

    Item 9.
    Notice of Dissolution of Group.

    Not applicable.

    Item 10.
    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: November 13, 2024

     
    JEFFERIES LLC
         
     
    By:
    /s/ Michael J. Sharp
     
    Name:
    Michael J. Sharp
     
    Title:
    Executive Vice President, General Counsel and Secretary

     
    JEFFERIES FINANCIAL GROUP INC.
         
     
    By:
    /s/ Michael J. Sharp
     
    Name:
    Michael J. Sharp
     
    Title:
    Executive Vice President and General Counsel



    Get the next $VATE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VATE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VATE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • INNOVATE Corp. Announces First Quarter 2025 Results

      - Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31,  2025   2024  Increase / (Decrease)Revenue$274.2  $315.2  (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(

      5/6/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor

      4/16/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

      - Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31,  2024   2023  Increase / (Decrease)  2024   2023  Increase / (Decrease)Revenue$236.6  $361.0  

      3/31/25 4:04:24 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Financials

    Live finance-specific insights

    See more
    • INNOVATE Corp. Announces First Quarter 2025 Results

      - Infrastructure: DBM Global first quarter revenue of $264.9 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") System Received FDA Approval to Assess Kidney Function -- Spectrum: Expects commercial opportunities in datacasting to generate revenue by the end of the year - NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the first quarter. Financial Summary (in millions, except per share amounts)Three Months Ended March 31,  2025   2024  Increase / (Decrease)Revenue$274.2  $315.2  (13.0)%Net loss attributable to common stockholders and participating preferred stockholders$(24.8) $(

      5/6/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

      NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE:VATE) ("INNOVATE" or the "Company") announced today that it will release its financial results for the first quarter 2025 on Tuesday, May 6, 2025, after market close. The Company will host an earnings conference call reviewing these results, its operations and strategy on the same day, beginning at 4:30 p.m. ET. Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the internet and can be accessed by all interested parties through INNOVATE's Investor Relations website at www.innovate-ir.com. To listen to the live call, please go to the "Investor

      4/16/25 4:05:39 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. Announces Fourth Quarter and Full Year 2024 Results

      - Infrastructure: DBM Global fourth quarter revenue of $225.7 million -- Life Sciences: MediBeacon® Transdermal GFR ("TGFR") system received FDA approval to assess kidney function -- Spectrum: Broadcasting achieved double-digit revenue growth in the fourth quarter and full year 2024 - NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE) announced today its consolidated results for the fourth quarter. Financial Summary (in millions, except per share amounts)Three Months Ended December 31, Year Ended December 31,  2024   2023  Increase / (Decrease)  2024   2023  Increase / (Decrease)Revenue$236.6  $361.0  

      3/31/25 4:04:24 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Sena Michael J. covered exercise/tax liability with 5,355 shares, decreasing direct ownership by 4% to 123,893 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      3/17/25 5:09:56 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Chief Financial Officer Sena Michael J. covered exercise/tax liability with 862 shares and was granted 12,946 shares, increasing direct ownership by 10% to 129,248 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      3/13/25 5:19:12 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Director Glazer Avram A received a gift of 4,195,804 shares and gifted 4,195,804 shares, decreasing direct ownership by 99% to 37,621 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      12/18/24 4:13:57 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by INNOVATE Corp.

      SC 13G/A - INNOVATE Corp. (0001006837) (Subject)

      11/13/24 9:30:32 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Amendment: SEC Form SC 13D/A filed by INNOVATE Corp.

      SC 13D/A - INNOVATE Corp. (0001006837) (Subject)

      6/21/24 7:05:53 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form SC 13D/A filed by INNOVATE Corp. (Amendment)

      SC 13D/A - INNOVATE Corp. (0001006837) (Subject)

      4/1/24 4:18:15 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    SEC Filings

    See more
    • SEC Form 10-Q filed by INNOVATE Corp.

      10-Q - INNOVATE Corp. (0001006837) (Filer)

      5/6/25 4:16:18 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • INNOVATE Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INNOVATE Corp. (0001006837) (Filer)

      5/6/25 4:09:09 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • SEC Form DEFA14A filed by INNOVATE Corp.

      DEFA14A - INNOVATE Corp. (0001006837) (Filer)

      4/28/25 4:16:15 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Interim CEO Voigt Paul bought $99,500 worth of shares (25,000 units at $3.98) (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      11/21/24 4:49:08 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $166,383 worth of shares (43,785 units at $3.80), increasing direct ownership by 26% to 211,655 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      9/16/24 4:17:05 PM ET
      $VATE
      Metal Fabrications
      Industrials
    • Interim CEO Voigt Paul bought $106 worth of shares (176 units at $0.60), increasing direct ownership by 0.01% to 1,678,695 units (SEC Form 4)

      4 - INNOVATE Corp. (0001006837) (Issuer)

      6/17/24 4:36:10 PM ET
      $VATE
      Metal Fabrications
      Industrials

    $VATE
    Leadership Updates

    Live Leadership Updates

    See more
    • MediBeacon Inc. Appoints Dr. Steve Miller as Chief Medical Officer

      MediBeacon expands management team as enrollment in Phase 3 study focused on kidney disease is completed ST. LOUIS, May 16, 2023 /PRNewswire/ -- MediBeacon Inc., a portfolio company within the Pansend Life Sciences segment of INNOVATE Corp. (NYSE:VATE), today announced the appointment of Dr. Steve Miller as chief medical officer. In this role, Dr. Miller will be focused on driving a range of clinical and strategic initiatives. Dr. Miller formerly served as executive vice president and chief clinical officer at Cigna, where he led the company's clinical policy, quality, and per

      5/16/23 7:00:00 AM ET
      $VATE
      Metal Fabrications
      Industrials
    • Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

      Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced the appointment of Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary. Mr. Ferraro will be responsible for managing Catalent's global legal and compliance operations. He will be based at the company's headquarters in Somerset, New Jersey, head up the company's Legal Leadership Team, and serve on its Executive Leadership Team, reporting directly to Catalent's Executive Vice President and Chief Administrative Officer, Steven Fasman. This press release features multimedia. View the full release here: https:/

      2/13/23 8:00:00 AM ET
      $CTLT
      $PSEC
      $VATE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Finance: Consumer Services
      Finance
    • INNOVATE Corp. Announces Appointment of Amy Wilkinson to the Board of Directors

      NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- INNOVATE Corp. ("INNOVATE" or the "Company") (NYSE:VATE), today announced the appointment of Amy Wilkinson to fill the remaining vacancy on the INNOVATE Board of Directors. "Amy brings a unique blend of management expertise and global business and policy experience, and we are confident she will help guide us in our mission to drive shareholder value across our Infrastructure, Life Sciences and Spectrum operating segments," said Avie Glazer, Chairman of INNOVATE. "Amy's leadership and strategy consulting experience advising Fortune 500 companies will be a valuable addition to our Board," said Wayne Barr, Jr., Chief Executive Officer of INNOVATE

      8/2/22 4:15:00 PM ET
      $VATE
      Metal Fabrications
      Industrials